Marinus Pharmaceuticals Appoints Christine Silverstein to Its Bd of Directors
Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target Cut to $23.00
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) had its price target lowered by SVB Leerink from $27.00 to $23.00 in a research report sent to investors on Monday, Benzinga reports. SVB Leerink cu
SVB Leerink Comments on Marinus Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:MRNS)
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Rating) – Investment analysts at SVB Leerink cut their FY2023 earnings estimates for shares of Marinus Pharmaceuticals in a report issued on Monday
Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at Royal Bank of Canada
Royal Bank of Canada assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) in a report published on Friday morning, The Fly reports. The firm issued an outperform rating an
SVB Securities Adjusts Price Target on Marinus Pharmaceuticals to $23 From $27, Maintains Outperform Rating
09:16 AM EST, 01/23/2023 (MT Newswires) -- Marinus Pharmaceuticals (MRNS) has an average buy rating and price target range of $12 to $50, according to analysts polled by Capital IQ. Price: 5.7, Change
Marinus Pharmaceuticals Is Maintained at Outperform by SVB Leerink
Marinus Pharmaceuticals Price Target Cut to $23.00/Share From $27.00 by SVB Leerink
SVB Leerink Maintains Outperform on Marinus Pharma, Lowers Price Target to $23
SVB Leerink analyst Marc Goodman maintains Marinus Pharma with a Outperform and lowers the price target from $27 to $23.
Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Royal Bank of Canada
Analysts at Royal Bank of Canada initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) in a report issued on Friday, The Fly reports. The firm set an "outperform" rating
Cosmos, InMed Top Healthcare Gainers; Innovative, Panbela Lead Losers' Pack
Loading...
No Stock Yet